GlassScriptPhysician profile
Mohammad Djafari
NPI 1669461711
$2,318.84
in general payments reported to CMS, 2019-2025
15 companies · $541 in 2025
The $541 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $361 · 2021: $409 · 2022: $427 · 2023: $295 · 2024: $135 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $361.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $356.43 | 2019-2022 | |
| Biofire Diagnostics, LLC | $281.71 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $249.91 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Corium, LLC | $179.65 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $176.03 | 2022-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $166.66 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $145.32 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.34 | 2019-2022 | |
| Seqirus USA INC | $92.74 | 2021-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Genentech USA, INC. | $87.03 | 2019-2021 | |
| Sobi, INC | $50.10 | 2021-2023 | Synagis |
| Ironshore Pharmaceuticals INC. | $41.71 | 2023 | Jornay Pm |
| Adlon Therapeutics L.P. | $16.18 | 2020 | |
| Kaleo, INC. | $15.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Djafari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.